Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03873064 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Body Mass Index (BMI) and Quality of Life (QoL) in Cancer Patients

Study acronym: BMI-QoL
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from University of Rome Tor Vergata

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 4 more changesShow less
    • Secondary endpoint revised
    • Study description expanded, about 74 words
    • Publications: details revised at 8 of 8 entries
    • Eligibility criteria expanded, about 5 words
  2. Primary completion date: Jan 2021 to Jan 15, 2029
    • Study completion date: Jan 2022 to Jan 15, 2034
    v3
  3. Study description shortened, about 331 wordsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
BMI is a simple and widely recorded variable that may capture obesity or cachexia in cancer patients. How BMI is associated to health-related quality of life (HR-QoL) in such patients is poorly investigated. High BMI may be associated to obesity, an increased burden of comorbidity, reduced physical activity and, in some settings, to more aggressive oncological disease. On the other hand, low BMI may reflect enhanced weight loss, cachectic syndrome, higher tumor burden and adverse prognostic features which all deteriorate quality of life. The aim of the present study is to evaluate the association of BMI and HR-QoL as measured by the EORTC-QLQ-C30 or the EQ-5D-5L questionnaire in several cancer settings (such as localized vs metastatic or distinct primary tumors).
Trial Details
NCT Number NCT03873064
Lead Sponsor University of Rome Tor Vergata
Collaborators: S.I.C.O.G. partners
Conditions
(from sponsor)		 Neoplasm Malignant, Body Weight, Quality of Life
Related terms Body Weight, Neoplasm Metastasis, Neoplasms
Enrollment 1,380 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov